Lundbeck has initiated phase I trial of acquired candidate

The first patients have been recruited and dosed in a phase I study with a potential new treatment for neurological conditions, Lu AG22515, which Lundbeck acquired last October.
In October, Lundbeck bought a phase I ready candidate from Aprilbio. Now, it's been sent to clinic | Photo: Mik Eskestad/ERH
In October, Lundbeck bought a phase I ready candidate from Aprilbio. Now, it's been sent to clinic | Photo: Mik Eskestad/ERH
by mikkel aabenhus hemmingsen, translated by daniel pedersen

For the first time, a person has been dosed with Lu AG22515, a candidate that Lundbeck acquired for USD 16m upfront payment from South Korean biotech company Aprilbio in October last year, in a deal which also included potential milestone payments of USD 432m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading